After finishing at $10.65 in the prior trading day, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) closed at $10.49, down -1.50%. On the day, 3686322 shares were traded.
Ratios:
Our goal is to gain a better understanding of RXRX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.70 and its Current Ratio is at 4.70. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 22, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.
On September 16, 2022, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $20.KeyBanc Capital Markets initiated its Overweight rating on September 16, 2022, with a $20 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 19 ’24 when Borgeson Blake sold 20,054 shares for $10.79 per share. The transaction valued at 216,423 led to the insider holds 7,252,755 shares of the business.
Secora Michael sold 25,000 shares of RXRX for $275,815 on Mar 13 ’24. The Chief Financial Officer now owns 1,204,179 shares after completing the transaction at $11.03 per share. On Mar 12 ’24, another insider, Secora Michael, who serves as the Chief Financial Officer of the company, sold 25,000 shares for $10.46 each. As a result, the insider received 261,375 and left with 1,191,679 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2.46B and an Enterprise Value of 2.12B. For the stock, the TTM Price-to-Sale (P/S) ratio is 50.79 while its Price-to-Book (P/B) ratio in mrq is 5.29. Its current Enterprise Value per Revenue stands at 48.25 whereas that against EBITDA is -6.88.
Stock Price History:
Over the past 52 weeks, RXRX has reached a high of $16.75, while it has fallen to a 52-week low of $4.54. The 50-Day Moving Average of the stock is 11.14, while the 200-Day Moving Average is calculated to be 9.31.
Shares Statistics:
The stock has traded on average 7.18M shares per day over the past 3-months and 7.42M shares per day over the last 10 days, according to various share statistics. A total of 226.26M shares are outstanding, with a floating share count of 146.54M. Insiders hold about 32.11% of the company’s shares, while institutions hold 77.29% stake in the company. Shares short for RXRX as of Feb 29, 2024 were 42.82M with a Short Ratio of 5.96, compared to 38.27M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 18.25% and a Short% of Float of 27.40%.
Earnings Estimates
Its stock is currently analyzed by 6 different market analysts. On average, analysts expect EPS of -$0.42 for the current quarter, with a high estimate of -$0.39 and a low estimate of -$0.46, while EPS last year was -$0.34. The consensus estimate for the next quarter is -$0.42, with high estimates of -$0.38 and low estimates of -$0.46.
Analysts are recommending an EPS of between -$1.49 and -$2.1 for the fiscal current year, implying an average EPS of -$1.73. EPS for the following year is -$1.91, with 7 analysts recommending between -$1.12 and -$3.5.
Revenue Estimates
6 analysts predict $12.65M in revenue for the current quarter. It ranges from a high estimate of $20.8M to a low estimate of $10M. As of the current estimate, Recursion Pharmaceuticals Inc’s year-ago sales were $12.13M, an estimated increase of 4.30% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $13.17M, an increase of 19.50% over than the figure of $4.30% in the same quarter last year. There is a high estimate of $20.8M for the next quarter, whereas the lowest estimate is $10.9M.
A total of 7 analysts have provided revenue estimates for RXRX’s current fiscal year. The highest revenue estimate was $83.3M, while the lowest revenue estimate was $43M, resulting in an average revenue estimate of $56.16M. In the same quarter a year ago, actual revenue was $44.58M, up 26.00% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $88.43M in the next fiscal year. The high estimate is $254.9M and the low estimate is $41.89M. The average revenue growth estimate for next year is up 57.50% from the average revenue estimate for this year.
